Indication

Atherosclerotic cardiovascular disease

Atherosclerotic cardiovascular disease is an umbrella clinical term encompassing disorders of the arterial vascular system caused by atherosclerosis, predominantly affecting adult populations. Read more about Atherosclerotic cardiovascular disease

205 drugs 99 manufacturers

Advertisement

Drugs that treat it

Common Atherosclerotic cardiovascular disease therapies.

Showing 100–108 of 205 drugs

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
CAMBER PHARMACE

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
LAURUS LABS LIM

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
MICRO LABS USA,

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

LOVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+7
APHENA PHARMA S

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
SOLCO HEALTHCAR

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
QUALITY CARE
Filter & compare in the drug finder →Opens the drug finder with Atherosclerotic cardiovascular disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Atherosclerotic cardiovascular disease.

Atherosclerotic cardiovascular disease is an umbrella clinical term encompassing disorders of the arterial vascular system caused by atherosclerosis, predominantly affecting adult populations.

Pathophysiologically, it is initiated by endothelial injury and chronic vascular inflammation, leading to subendothelial lipid accumulation and the formation of fibrofatty plaques within medium and large arteries.

Over time, plaque expansion, luminal stenosis, or acute plaque rupture and thrombosis compromise organ perfusion, clinically manifesting as coronary heart disease, ischemic cerebrovascular disease, peripheral artery disease, or aortic atherosclerotic disease.

Personalize your experience

Follow Atherosclerotic cardiovascular disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it